Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

CD19, a B-cell surface protein, is expressed across B-cell development and it is expressed on almost all B-cell malignancies, such as ALL, chronic lymphocytic leukemia (CLL) and several non ...

2025年1月13日，科济药业宣布，公司自主研发的一款靶向CD19/CD20的通用型CAR-T细胞治疗候选产品KJ-C2219（研发药代号）已完成 ...

In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...